PATENT CLAIM ANALYSIS

Application Number: 16033477
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "143100"]

Abstract:
The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.

Claim (Index 24):
The method of  claim 22 , wherein the antibody or antigen-binding fragment of the first ADC comprises heavy and light chain complementarity determining regions comprising SEQ ID NOs: 36, 38, 40, 44, 46, and 48.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 95.0
- Lexical Diversity: 1.67925
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15170628', '14643886', '15051580', '14464297', '15289032']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7782142534251753
- 35 USC 102 Novelty (BERT): 0.6389630190040112
- Combined Prediction Score: 0.7642891299830589
- Mean Citation Score: 582.8586280000002
- Max Citation Score: 722.5108
- Similarity Product: 533.9850652069567

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test